An 11-year-old girl in the UK has become the first patient to receive a gene therapy aimed at halting or preventing loss of sight from a rare inherited condition. Multiple outlets report that the girl, Catherine L’Estrange, from North Acton in London, was diagnosed with the genetic disorder as a baby. The therapy is described as innovative and sight-saving, with the goal of preserving her vision rather than correcting existing blindness. Coverage notes that she is hopeful the treatment will enable her to continue everyday activities she values, particularly reading books. While the articles characterize the intervention as groundbreaking, they do not provide additional clinical outcomes or long-term results, focusing instead on the significance of being the first UK patient to undergo the treatment. The reports present the development as a milestone for patients with this type of genetic condition, with the therapy offering the prospect of slowing or stopping further deterioration of sight. The girl’s anticipation of maintaining her reading is cited as a central personal motivation for undergoing the procedure.